Brief: Obseva Announces Additional Phase 3 Primrose 1 And 2 Study Results
10/12/2020 06:01
Dec 10 (Reuters) - Obseva SA OBSN.S :
* OBSEVA ANNOUNCES ADDITIONAL PHASE 3 PRIMROSE 1 AND 2 STUDY
RESULTS CONFIRMING SUSTAINED EFFICACY AND CONTINUED SAFETY OF
LINZAGOLIX IN THE TREATMENT OF UTERINE FIBROIDS
* PRIMROSE 2 76-WEEK RESULTS SHOW CONTINUED PAIN REDUCTION
AND
DEMONSTRATE EVIDENCE OF BONE MINERAL DENSITY (BMD) RECOVERY
FOLLOWING 52 WEEKS OF TREATMENT
* PRIMROSE 1 52-WEEK RESULTS CONFIRM SUSTAINED EFFICACY AND
CONTINUED SAFETY OF LINZAGOLIX (YSELTY(®)), WITH A POTENTIAL
BEST-IN-CLASS HIGH-DOSE OPTION (200 MG WITH ADD-BACK THERAPY
ABT )
Source text for Eikon: ID:nGNEbyCWHj
Further company coverage: OBSN.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Obseva SA
See all newsBrief: Obseva Announces Wind-Down Of Operations And Likely Not Going To Be Able To Satisfy Requirements For Maintaining Its Listing
Brief: Obseva Applies For Moratorium To Facilitate Pivotal Deals
Brief: Obseva SA Says Xoma Will Receive Full Worldwide Rights On Ebopiprant Following Termination Of License Agreement With Organon
Brief: Obseva Appoints Fabien De Ladonchamps As Chief Executive Officer Effective May 1, 2023
Brief: Obseva Announces Change Of Central Securities Depositary